Literature DB >> 15648545

Plasma and tissue chromogranin in patients with adrenocortical adenomas.

G P Bernini1, A Moretti, M Borgioli, M Bardini, P Miccoli, P Berti, F Basolo, P Faviana, R Birindelli, A Salvetti.   

Abstract

Adrenal adenomas frequently arise from cortical islets in the medulla, and these islets seem to present a greater risk for pathological growth than cortical cells within the adrenal cortex. Chromogranin A (CgA), a glycoprotein co-stored in secreting granules and co-released with resident hormones of chromaffin cells, behaves as a prohormone, generating several biologically active peptides capable of influencing growth, morphogenesis and progression of endocrine tumors. The aim of our study was to investigate whether chromaffin cells may be involved in the development and growth of adrenocortical adenomas. We enrolled 19 patients (12 females and 7 males, mean+/-SD age 54.9+/-11.2 yr, age range 34-75 yr) with incidental, non-functioning, benign adrenocortical adenomas, and measured circulating levels of CgA, catecholamines and creatinine before and 2 months after surgery. Plasma CgA was evaluated by immunoradiometric assay. Testing for CgA immunoreactivity in the removed tissues was performed by immunohistochemical analysis. Mean plasma CgA did not significantly change following surgery (before 73.7+/-15.2 ng/ml; after 68.9+/-14.8 ng/ml). Individual CgA values indicated that 4 patients had plasma CgA levels above our cut-off of normality. After mass removal, CgA further increased in 2 cases, decreased in 1 and normalized in 1. No variation in CgA levels was found in the other patients. No correlation was observed between CgA and the variables measured, except between CgA and plasma creatinine (r=0.472, p<0.05). Histopathological evaluation revealed adrenocortical adenomas in all cases and immunohistochemical analysis detected no CgA immunoreactivity in any specimen. Our results show that in human adrenocortical adenomas CgA is not expressed and that removal of the mass does not modify plasma CgA levels. For these reasons the endocrine involvement of local CgA in adrenocortical tumorigenesis is unlikely.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15648545     DOI: 10.1007/BF03346275

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide.

Authors:  K Lugardon; S Chasserot-Golaz; A E Kieffer; R Maget-Dana; G Nullans; B Kieffer; D Aunis; M H Metz-Boutigue
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

2.  Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain.

Authors:  A Gasparri; A Sidoli; L P Sanchez; R Longhi; A G Siccardi; P C Marchisio; A Corti
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  Chromogranin A alters ductal morphogenesis and increases deposition of basement membrane components by mammary epithelial cells in vitro.

Authors:  J V Soriano; M S Pepper; L Taupenot; M F Bader; L Orci; R Montesano
Journal:  Biochem Biophys Res Commun       Date:  1999-06-16       Impact factor: 3.575

4.  Neurotransmitters and neuropeptides in the differential regulation of steroidogenesis in adrenocortical-chromaffin co-cultures.

Authors:  M Ehrhart-Bornstein; A Haidan; S Alesci; S R Bornstein
Journal:  Endocr Res       Date:  2000-11       Impact factor: 1.720

Review 5.  Molecular biology of the chromaffin cell.

Authors:  José-María Trifaro
Journal:  Ann N Y Acad Sci       Date:  2002-10       Impact factor: 5.691

6.  Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A.

Authors:  K Lugardon; R Raffner; Y Goumon; A Corti; A Delmas; P Bulet; D Aunis; M H Metz-Boutigue
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

7.  Chromogranin A peptide-specific antisera and high-performance size exclusion chromatography demonstrate amino-terminal and carboxy-terminal fragments of the native molecule in human cell lines.

Authors:  D W Brandt; D W Burton; R Hogue-Angeletti; L J Deftos
Journal:  Proc Soc Exp Biol Med       Date:  1994-04

8.  Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites.

Authors:  M H Metz-Boutigue; P Garcia-Sablone; R Hogue-Angeletti; D Aunis
Journal:  Eur J Biochem       Date:  1993-10-01

Review 9.  Incidentally discovered adrenal masses.

Authors:  R T Kloos; M D Gross; I R Francis; M Korobkin; B Shapiro
Journal:  Endocr Rev       Date:  1995-08       Impact factor: 19.871

10.  A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245).

Authors:  F Degorce; Y Goumon; L Jacquemart; C Vidaud; L Bellanger; D Pons-Anicet; P Seguin; M H Metz-Boutigue; D Aunis
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more
  3 in total

1.  Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines.

Authors:  K Miehle; J Kratzsch; J W M Lenders; R Kluge; R Paschke; C A Koch
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

2.  PREDICTIVE VALUE OF CHROMOGRANIN A IN A DIAGNOSIS TOWARDS PHEOCHROMOCYTOMA IN ADRENAL INCIDENTALOMA.

Authors:  S K Zawadzka-Leska; M Radziszewski; K Malec; A Stadnik; U Ambroziak
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

3.  Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

Authors:  Paweł Gut; Agata Czarnywojtek; Jakub Fischbach; Maciej Bączyk; Katarzyna Ziemnicka; Elżbieta Wrotkowska; Maria Gryczyńska; Marek Ruchała
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.